Laquinimod, Huntington's disease, and disease modification
-
Published:2024-01
Issue:
Volume:
Page:
-
ISSN:1474-4422
-
Container-title:The Lancet Neurology
-
language:en
-
Short-container-title:The Lancet Neurology
Subject
Neurology (clinical)
Reference10 articles.
1. Huntington disease;Ghosh;Handb Clin Neurol,2018
2. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities;Tabrizi;Lancet Neurol,2022
3. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers;Politis;Neurobiol Dis,2015
4. Safety and efficacy of laquinimod for Huntington's disease (Legato-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study;Reilmann;Lancet Neurol,2024
5. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease;Cubo;Mov Disord,2012